Kate Spade died 7 years ago: What to know about the iconic fashion designer
Spade's death on June 5, 2018, stunned the fashion world, highlighting the silent struggles behind one of the industry's biggest names and, along with the death of Anthony Bourdain three days later, sparked a broader conversation about mental health amidst fame and success.
A two-time Council of Fashion Designers of America award winner, Spade left behind a brand that captivated young women in the '90s and early aughts that endures today.
Born Katherine Brosnahan in Kansas City, she co-founded her eponymous designer brand in 1993 with her future husband and business partner Andy Spade, the brother of comedian David Spade, in their New York City apartment.
Started with hand-taped prototypes, Kate Spade became a rapid success, expanding to shoes, luggage and other accessories. Spade relinquished any ownership of her brand in the mid-2000s, which would change hands a few times before landing at Tapestry, Inc., formerly Coach, Inc., after a $2.4 billion purchase in 2017.
Spade was found dead in her Upper East Side apartment in New York City. She was 55. Her cause of death was ruled suicide by hanging.
In a statement reported by media at the time, Andy Spade said his late wife had "suffered from depression and anxiety for many years" but "was actively seeking help and working closely with her doctors to treat her disease, one that takes far too many lives."
Her death was followed by Anthony Bourdain's suicide three days later.
"There was no indication and no warning that she would do this. It was a complete shock," Andy Spade continued. "There were personal demons she was battling."
Kate Spade's best friend Elyce Arons, who is writing a memoir titled "We Might Just Make It After All" about their friendship, said the couple "were trying to work things out," she told People in an interview published June 3. The book is set for release on June 17 through Simon & Schuster.
Spade's daughter Frances Beatrice Valentine Spade was 13 at the time of her death. Police reported at the time that she left Frances, now 20, a note.
In 2016, Kate Spade turned to a new brand based around her daughter, the luxury footwear and handbag company Frances Valentine, with which she remained active until her death.
If you or someone you know may be struggling with suicidal thoughts, you can call 988 any time day or night, or chat online. Crisis Text Line also provides free, 24/7, confidential support via text message to people in crisis when they dial 741741.
This article originally appeared on USA TODAY: Kate Spade death: Fashion designer died 7 years ago
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
3 hours ago
- Yahoo
Compared to Estimates, Vimeo (VMEO) Q2 Earnings: A Look at Key Metrics
Vimeo, Inc. (VMEO) reported $104.65 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 0.3%. EPS of $0.04 for the same period compares to $0.06 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $105.76 million, representing a surprise of -1.05%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Vimeo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: ARPU - Self-Serve: $197.00 versus $189.45 estimated by two analysts on average. ARPU - Vimeo Enterprise: $24,705.00 compared to the $25,001.00 average estimate based on two analysts. Revenue- Self-Serve: $57.56 million versus the two-analyst average estimate of $56.4 million. Revenue- Vimeo Enterprise: $25 million versus the two-analyst average estimate of $26.3 million. The reported number represents a year-over-year change of +24.7%. Revenue- Other: $1.63 million compared to the $1.79 million average estimate based on two analysts. The reported number represents a change of -89.6% year over year. Revenue- Add-Ons: $8.2 million versus the two-analyst average estimate of $8.15 million. Revenue- OTT: $12.27 million compared to the $12.05 million average estimate based on two analysts. View all Key Company Metrics for Vimeo here>>> Shares of Vimeo have returned -7.1% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vimeo, Inc. (VMEO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
SEMrush Holdings, Inc. (SEMR) Lags Q2 Earnings Estimates
SEMrush Holdings, Inc. (SEMR) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -37.50%. A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.07, delivering no surprise. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. SEMrush, which belongs to the Zacks Internet - Software industry, posted revenues of $108.89 million for the quarter ended June 2025, in line with the Zacks Consensus Estimate. This compares to year-ago revenues of $90.95 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. SEMrush shares have lost about 28.5% since the beginning of the year versus the S&P 500's gain of 6.1%. What's Next for SEMrush? While SEMrush has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for SEMrush was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.09 on $114.98 million in revenues for the coming quarter and $0.35 on $449.65 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Broadridge Financial Solutions (BR), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 5. This technology outsourcing company is expected to post quarterly earnings of $3.51 per share in its upcoming report, which represents a year-over-year change of +0.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Broadridge Financial Solutions' revenues are expected to be $2.05 billion, up 5.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SEMrush Holdings, Inc. (SEMR) : Free Stock Analysis Report Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
